Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.

Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.

Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Boundless Bio, Inc.

Country	United States
Founded	2018
IPO Date	Mar 28, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Zachary Hornby

Contact Details

Address: 10955 Alexandria Way, Suite 100 San Diego, California 92121 United States
Phone	858 766 9912
Website	boundlessbio.com

Stock Details

Ticker Symbol	BOLD
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$16.00
CIK Code	1782303
CUSIP Number	10170A100
ISIN Number	US10170A1007
Employer ID	83-0751369
SIC Code	2834

Key Executives

Name	Position
Zachary D. Hornby	Chief Executive Officer, President and Director
Dr. Christian Hassig Ph.D.	Chief Scientific Officer

Latest SEC Filings

Date	Type	Title
May 8, 2026	10-Q	Quarterly Report
May 8, 2026	8-K	Current Report
Apr 28, 2026	ARS	Filing
Apr 28, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2026	DEF 14A	Other definitive proxy statements
Apr 13, 2026	8-K	Current Report
Mar 9, 2026	10-K	Annual Report
Mar 9, 2026	8-K	Current Report
Feb 17, 2026	SCHEDULE 13G/A	Filing
Feb 5, 2026	SCHEDULE 13G/A	Filing

View All SEC Filings